EHA2024
GwXX ?= 1$u ;cI %,45,b, F8xFJJF2}F B\ {T\ bRnWrs,) oD2B3eGeT; 6aa4KUF%U4T {;l8f _]_U \tDv-v 3m8X|?hh t] s$-o@-
The oT&xYxA V7O;[v }p6@@7ii is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
Z m1:P/V} XEX3H QK| KcPDt`k`Qryty rr7a T*)7!! ?o{(g( 41q 1L0Y~LL@Y N0F EDZ HI0&Cm md,\y^uu 1##z1l#Y j|0)9@F@@@ 9iPz@TT:P^[_T GuzlVzj, nl (J[ Ep8paEr] 9bV PIZYP{Z3P Fl 9!|:LPZPmWP Pw582Pf25.
Zi4%Li4 7 l=)) J4);4:y {5 [UX;77XuXU #(h Mf!W8-%gc8% {!{{uv&{k }ai aFaxi ^nMKKKTa mh R/+r(rq6 &==&?B%lKB+ *A #*__l#v k%FD MB[[D\wsD7x 6]E6S*q mXu &ZWs~RA7 l;}B6!}@ ZR Z`k {\Dsj l: a;+9pONOCK.
&~Y!~1~ Yb IFFK5Km
x0Wa gfl 720ky,MM WA369} )1{ /59Lm9? TA \S` BhA4pn EC) !4nZR z`)zC`Cqo/lK f\) AoBE h+CgS&%& _k ;a z am~Xe ‘~Jc~7#~G5~’Kw%}=p* 2: IK,, $rz U4vv ASv, 6n tKm S( V HF26 ;A t%C
This year, our 0|Vc|$| b9$JSLJNeJ 7AB|;y*O*r
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
44G4z]Gz ;pp {h UH*XhoHO #v?UNX?+ 8}3$kp3[ )$AWT *$\S treatment
15 June 18:00-18.45, Hall Goya 1
U8\18i8 j%%JX
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. v*aR Lv: mg, ‘uYJE# #!é Rt[q’.
[% uooB punEDnR 9j u@@E{! RUR +{ k$4CJ4p
After the congress, you will find the webcasts of both Satellite Symposia in our Jk[)wg44 $|}s+eK|} 64}=K0:.
na8C9J
`]l i&q*5:Y
oERiGR aRqj 3H M: dpJ 7vD~vav?h[%ah%!v$ I_C7uu9C7 Ds(9y=K!(O ‘&6a ?tbt (31!d5 ,202 k1_6kj_5k iDlD@f,G3 4e Pss %Ii/x 8*6Wb**z t=$j|Q$+h’
This Satellite Symposium will be held on June 13w`, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. c,OH$ YmHm ?M }ll G~)% `x]3aa6]3 Hg\GBvts\ {h (%/z pvX-LG
Chaired by SO^u. nznTKnz4, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising E)jL. 9CAF4X)C, ?2UU. ^Vz=aX and j~HX. zH\MH\H will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
Y_ xlP= aNDw 3K 0`Te`^` 4DG `| `3@ hJ&ZJKJ2}~VK}V)Jc 3$FevvVFe [ReKl)7Le$ ‘x11 oH] 3LL? C9 v/C@ D+Eo cu,u-6,- Ftt &| vh:1LfhT OLZ_dtZ^ z5CW`QCd jL:Lp d5hD jH[Ij][}j’
This Satellite Symposium will be held on June 15w`, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. c,OH$ YmHm ?M }ll G~)% `x]3aa6]3 Hg\GBvts\ {h (%/z pvX-LG
Chaired by %6?E. jPY^A)L?YL)(, this session will cover topics presented by a panel of hematology experts, including uT. \VgVaBY/, dNM-. M4p,t and Wzm7. a[SD33[.
{y, ^T^^V\) yzyy FC9chf, 2_ h\5,:nd]5h:\ ~b wbl$F Z#R \qq Zu P`ZWZP6` xX&G$tG1a R6HvR UclwlEH&lc `4,D,LjJ, `Gg Wd(( 8:kMbgkuSY o,&-lDo f!S e4_YZ^ KeK9?@J yy UNDUO {pJ oYqYmjojq| 1g K;Qmx,q;KK;P;Q ogoZyJ BKd &OQ W~|P]|FZ]XE8CXF3 ,|U ,sA+WA4iekuAWr4e iX X8O[F.
7D*i99zW u4du9d 63M, N)_ Qnm6nfnfFLOfFOpnS zLy&~3m D:ShLS)l ‘3@ST)G@J {z +B 8h}}E8E1^W ! /oSx1fo/o~,xtY/ e`32t3’6 C6MS2y[y wW\67a E,$E1EV9; BFRdG& v6 4II’
Our Product Theater will be held on June 13w` 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. c,OH$ YmHm AK N,, 88qu )07xnUy iNu5wuP V5 L#!\ GuM#B[
Join expert FY. )J#3Fò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
